Effect of bezafibrate on hepatic oxidative stress: Comparison between conventional experimental doses and clinically-relevant doses in mice

Redox Report

Volumn 15, Issue 3, 2010, Pages 123-130

  Nakajima, Takero ^a   Tanaka, Naoki ^a,b   Li, Gang ^c   Hu, Rui ^d   Kamijo, Yuji ^a,b   Hara, Atsushi ^a   Aoyama, Toshifumi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HEBEI GENERAL HOSPITAL   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

bezafibrate; oxidative stress; peroxisome proliferator activated receptor (PPAR )

Indexed keywords

ACYL COENZYME A OXIDASE; BEZAFIBRATE; CYTOCHROME P450 4A; LIPID PEROXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVATION; ENZYME INDUCTION; FATTY ACID OXIDATION; LIVER INJURY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; LIVER; METABOLISM; MOUSE MUTANT; RANDOMIZATION;

MUS; RODENTIA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; BEZAFIBRATE; HUMANS; LIVER; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; PPAR ALPHA; PROTEIN KINASE C; RANDOM ALLOCATION; REACTIVE OXYGEN SPECIES;

EID: 77954164516     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/174329210X12650506623807     Document Type: Article

References (46)

1. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
2. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-27.
3. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154-1160.
4. Nagasawa T, Inada Y, Nakano S et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARαagonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006; 536: 182-191.
5. Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000; 95: 2990-2992.
6. Aoyama T, Peters JM, Iritani N et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α(PPARα). J Biol Chem 1998; 273: 5678-5684.
7. Kamijo Y, Hora K, Kono K et al. PPARα protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol 2007; 18: 3089-3100.
8. Nakajima T, Kamijo Y, Tanaka N et al. Peroxisome proliferatoractivated receptor α protects against alcohol-induced liver damage. Hepatology 2004; 40: 972-980.
9. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARα activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 2008; 118: 683-694.
10. Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activated receptor α. J Natl Cancer Inst 1998; 90: 1702-1709.
11. Yeldandi AV, Rao MS, Reddy JK. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat Res 2000; 448: 159-177.
12. Faiola B, Falls JG, Peterson RA et al. PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. Toxicol Sci 2008; 105: 384-394.
13. Bordelon NR, Romach BH, Brown HR, Miller RT. Gene expression patterns associated with fenofibrate-induced myopathy, 584. Toxicol CD off J Soc Toxicol 2005; 84: 119-120.
14. Jiao HL, Zhao BL. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol 2002; 185: 172-179.
15. Teissier E, Nohara A, Chinetti G et al. Peroxisome proliferatoractivated receptor αinduces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-α activation properties. Circ Res 2004; 95: 1174-1182.
16. Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual ligand for PPARαand PPARβ: studies using null mice. Biochim Biophys Acta 2003; 1632: 80-89.
17. Hays T, Rusyn I, Burns AM et al. Role of peroxisome proliferatoractivated receptor-α(PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 2005; 26: 219-227.
18. Nakajima T, Tanaka N, Kanbe H et al. Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via downregulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor α-independent mechanism. Mol Pharmacol 2009; 75: 782-792.
19. Nakajima T, Tanaka N, Sugiyama E et al. Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice. Biochem Pharmacol 2008; 76: 108-119.
20. Lee SS, Pineau T, Drago J et al. Targeted disruption of the αisoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995; 15: 3012-3022.
21. Akiyama TE, Nicol CJ, Fievet C et al. Peroxisome proliferatoractivated receptor-αregulates lipid homeostasis, but is not associated with obesity. J Biol Chem 2001; 276: 39088-39093.
22. Aoyama T, Yamano S, Waxman DJ et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 1989; 264: 10388-10395.
23. Aoyama T, Uchida Y, Kelley RI et al. A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem Biophys Res Commun 1993; 191: 1369-1372.
24. Aoyama T, Souri M, Ushikubo S et al. Purification of human verylong- chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest 1995; 95: 2465-2473.
25. Hashimoto T, Kuwabara T, Usuda N, Nagata T. Purification of membrane polypeptides of rat liver peroxisomes. J Biochem 1986; 100: 301-310.
26. Osumi T, Hashimoto T, Ui N. Purification and properties of acyl- CoA oxidase from rat liver. J Biochem 1980; 87: 1735-1746.
27. 2α. J Lipid Res 1990; 31: 1477-1482.
28. Furuta S, Miyazawa S, Hashimoto T. Purification and properties of rat liver acyl-CoA dehydrogenases and electron transfer flavoprotein. J Biochem 1981; 90: 1739-1750.
29. Uchida Y, Izai K, Orii T, Hashimoto T. Novel fatty acid β-oxidation enzymes in rat liver mitochondria. J Biol Chem 1992; 267: 1034-1041.
30. Furuta S, Hayashi H, Hijikata M, Miyazawa S, Osumi T, Hashimoto T. Complete nucleotide sequence of cDNA and deduced amino acid sequence of rat liver catalase. Proc Natl Acad Sci USA 1986; 83: 313-317.
31. Hara A, Radin NS. Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem 1978; 90: 420-426.
32. Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 1993; 26: 39-42.
33. Tanaka N, Moriya K, Kiyosawa K, Koike K, Aoyama T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor αin transgenic mice: implications for HCV-associated hepatocarcinogenesis. Int J Cancer 2008; 122: 124-131.
34. Nakamura S, Takamura T, Matsuzawa-Nagata N et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J Biol Chem 2009; 284: 14809-14818.
35. Okiyama W, Tanaka N, Nakajima T et al. Polyenephosphatidyl - choline prevents alcoholic liver disease in PPARα-null mice through attenuation of increases in oxidative stress. J Hepatol 2009; 50: 1236-1246.
36. Kane CD, Francone OL, Stevens KA. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARα. Gene 2006; 380: 84-94.
37. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009; 84: 705-712.
38. Anwer T, Sharma M, Pillai KK, Haque SE, Alam MM, Zaman MS. Protective effect of bezafibrate on streptozotocin-induced oxidative stress and toxicity in rats. Toxicology 2007; 229: 165-172.
39. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
40. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004; 34: 9-19.
41. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008; 47: 2127-2133.
42. Tanaka N, Sano K, Horiuchi A et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 413-418.
43. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARαagonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 1286-1296.
44. Nakano S, Nagasawa T, Ijiro T et al. Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-β1 in a cultured stellate cell line. Hepatol Res 2008; 38: 1026-1039.
45. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131.
46. Moriishi K, Mochizuki R, Moriya K et al. Critical role of PA28γin hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 2007; 104: 1661-1666.